Stocks are at all-time highs in 2026 the S&P 500 was last seen up 13% year-to-date. Despite weaker economic reports and ongoing geopolitical concerns, Wall Street still sees many stocks continuing to do well as 2027 approaches. In fact, some stocks are still seeing analysts upgrading their ratings to “Buy” and “Outperform” based on their own fundamentals.
Oggonomics tracks the daily flow of analyst upgrades, downgrades and initiations to find new ideas and overlooked opportunities for both long-term investors and short-term traders alike.
While investors should not ever rely on any single analyst report as the sole basis to buy or sell a stock, some significant implied upside is being seen in many research reports. Just don’t ever forget that analysts can get their thesis wrong — and there are no “money-back guarantees” ever issued in research reports in their forecasts.
All ratings and price targets have come from the firms named in this reporting. Oggonomics does not issue formal ratings and price targets of its own.
ALSO READ: TOP STOCKS TO SELL NOW!
These were the top analyst upgrades seen for Friday, August 7, 2026.
Atlassian (TEAM) was last seen trading up 30% at $145.00 on Friday after its earnings report shows that Ai fears were overblown and now may be a benefit rather than a risk. BofA upgraded Atlassian to Buy from Neutral and raised its price objective to $175 from $105, noting that revenue concerns are now behind it with strong 2027 guidance for cloud growth. The upgrade also cited that investors had underappreciated the value of Atlassian’s workflow and collaboration data to help it become an emerging AI beneficiary rather than a victim. Jefferies also reiterated its Buy rating and raised its price target on Atlassian to $200 from $150, citing similar notes to BofA.
Avita Medical (RCEL) was raised to Buy from Neutral with a $7 price target at BTIG, after noting its earnings showed better execution than in 2025 while its growth is broadening. The catch about looking at this upgrade is that the shares were up 24% at $5.90 right before Friday’s opening bell based on its strong earnings report.
Baker Hughes (BKR) was resumed at Morgan Stanley with an Overweight rating and $70 price target (versus $62.75 close), with the firm also calling it a top pick. As Baker Hughes has also evolved into a broader industrial energy technology platform (i.e. datacenters, industrial and new energy markets), all leading growth for the company. Baker Hughes has a 52-week range of $41.96 – $70.41 and a consensus price target of $71.
PubMatic, Inc. (PUBM) was last seen trading up 28% at $17.27 after investors cheered its earnings report, followed by two analyst upgrades. Raymond James upgraded PubMatic to Outperform from Market Perform and it has a $22 price target based on sustainable fundamental improvements and with the majority of its business now coming from higher-growth formats outside of the web (mobile apps and emerging businesses). Scotiabank raised its rating on PubMatic to Outperform from Sector Perform, but its price target was hiked all the way up to $21 from $8 in the call. Scotia cited that its AI story is pushing revenue growth, driving margins and free cash flow higher.
Quanta Services (PWR) was raised to Overweight from Sector Weight with a $807 price target (versus $667.84 prior close) at KeyBanc Capital Markets. Quanta is deemed a stronger stock among peers as a risk-off environment emerges for engineering and construction. Quanta’s 52-week range is $363.01 – $788.75 with a $767 consensus price target.
Replimune Group, Inc. (REPL) was raised to Outperform from Neutral and its price target was raised to $19 from $12 at Wedbush Securities. The shares were actually trading down 3% at $12.45 on Friday. The upgrade showed that the FDA’s accelerated approval of TUDRIQEV in combination with nivolumab to treat adults with unresectable advanced cutaneous melanoma is the first approval of its class despite having received two prior Complete Response Letters. Replimune has only a $1 billion market cap and a 52-week range of $1.50 – $13.40.
ALSO READ: DID GOLD JUST BOTTOM?
Space Exploration Technologies Corp. (SPCX) now its first earnings and post-IPO lock-up expiration behind it, and the independent research firm Argus raised its rating to Buy from Hold with a $160 price target. The firm cited robust growth in computing capacity despite higher capital spending expectations. SpaceX’s own forecast for a $100 billion run rate in revenues by year-end as significantly above the firm’s initial forecasts when it issued a Hold rating. SpaceX shares were indicated up 3% at $119 on Friday, with a post-IPO range of $104.83 – $225.64 and a consensus analyst price target that is still above $200.
Unity Software Inc. (U) has seen multiple upgrades on Friday after it posted strong revenues and adjusted EBITDA in that report. BofA raised Unity to Buy from Neutral and hiked its price objective $50 from $30, calling it a blowout quarter with sustainable growth through the end of 2027. Benchmark raised its rating to Buy from Hold with a $50 price target, and BTIG reiterated its Buy rating and raised its price target to $51 from $43. Deutsche Bank also raised Unity to Buy from Hold and hiked its price target to $50 from $31. Shares of Unity Software were indicated up 5% at $43.00 on Friday, with a 52-week range of $16.78 – $52.15.
